Several studies have demonstrated that the vitiligo disease activity and prognosis of cancer immunotherapy for melanoma correlate with the number and effector function of MSA-specific CD8+ T cells in the skin and melanoma, respectively (4–7). The gene discussed is CD8A; the disease is melanoma.